In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
J&J teams up with Orexo for respiratory drug development; terminated
18 Feb 2015
Orexo (working on therapeutics for pain and inflammatory conditions) has licensed Johnson & Johnson's Ortho-McNeil Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica NV (collectively OMJ) global rights to its OX-CLI and OX-ESI preclinical programs for asthma, COPD, and other inflammatory diseases. OMJ will also add a third internal drug candidate to the three-year-deal.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?